These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose levels. https://arunliel204346.techionblog.com/39328170/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide